Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tiratricol-Containing Products Not Dietary Supplements - U.S. Judge

This article was originally published in The Tan Sheet

Executive Summary

Tiratricol cannot be marketed as a dietary supplement because it has been the subject of an investigational new drug application since 1990, a Cape Girardeau, Mo. federal judge has ruled in an FDA enforcement action against Syntrax Innovations.

You may also be interested in...



Syntrax LipoKinetix Liver AERs Necessitate Product Removal – FDA

LipoKinetix should be withdrawn from the market due to reports linking the weight-loss supplement to "at least six" cases of serious liver injury, FDA states in a 1Nov. 19 letter to Chaufee, Mo.-based Syntrax Innovations

Syntrax LipoKinetix Liver AERs Necessitate Product Removal – FDA

LipoKinetix should be withdrawn from the market due to reports linking the weight-loss supplement to "at least six" cases of serious liver injury, FDA states in a 1Nov. 19 letter to Chaufee, Mo.-based Syntrax Innovations

Syntrax LipoKinetix Liver AERs Necessitate Product Removal – FDA

LipoKinetix should be withdrawn from the market due to reports linking the weight-loss supplement to "at least six" cases of serious liver injury, FDA states in a 1Nov. 19 letter to Chaufee, Mo.-based Syntrax Innovations

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092293

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel